Market Overview:
The global interferon alpha-2a biosimilar market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of chronic diseases, such as hepatitis C and hepatitis B, and the subsequent increase in demand for interferon alpha-2a biosimilars. Additionally, the increasing number of approvals for interferon alpha-2a biosimilars by regulatory authorities is also contributing to the growth of this market. On the basis of type, long-lasting type segment is expected to account for a larger share of the global interferon alpha-2a biosimilar market during the forecast period. This can be attributed to their longer half life as compared with ordinary type segments and their ability to provide sustained therapeutic effects over an extended period of time.
Product Definition:
Interferon alpha-2a biosimilar is a protein that is structurally similar to the naturally occurring human Interferon alpha-2a. It is used as a medication to treat certain types of cancer, hepatitis C, and multiple sclerosis.
Long-lasting Type:
The long-lasting type is also known as the interferon alpha-2a. It’s a subtype of interferon, which is a protein hormone that helps the immune system to respond to foreign substances like viruses, bacteria and tumor cells. Interferons are used in treating several diseases such as multiple sclerosis, cancer (small cell lung), hepatitis C virus infection and chronic fatigue syndrome among others.
Ordinary Type:
An ordinary type is a reference to the human leukocyte antigen (HLA) class I molecule, which is an important part of the immune system for normal body function. The HLA-class I molecules are majorly found on cell surfaces and present in two forms: non-covalent and covalent. Non-covalent form refers to an association between HLA protein and some ligands such as Fc or IgG1.
Application Insights:
Based on the application, the global interferon alpha-2a biosimilar market is segmented into hepatitis C, hepatitis B and other. Hepatitis C held the largest share in 2017 owing to high prevalence of chronic hepatitis infection across the globe. Moreover, introduction of new products in this segment is expected to trigger growth during forecast period. For instance, Taltz (ixekizumab) injection by Bioventus will be available for commercialization in early 2018; therefore, its launch is likely to contribute towards market growth during estimated time frame.
The other application segment includes indications related to rheumatoid arthritis and Crohn¢â‚¬â„¢s disease that have not been fully addressed by existing products currently available on the market. Therefore, development of new drugs for these indications would provide a significant boost towards industry growth over next few years. For instance.
Regional Analysis:
North America dominated the global market in 2017. High awareness levels regarding the benefits of biosimilars, presence of key players and large patient pool are some factors responsible for its largest share. The region is expected to maintain its position during the forecast period owing to continuous launch of new products and growing generic competition.
Asia Pacific is anticipated to witness fastest growth over the forecast period owing to rising incidences of chronic hepatitis B & C infections coupled with increasing per capita income in emerging countries such as China & India. Moreover, government initiatives encouraging interferon alpha-2a biosimilar usage are also likely to boost regional growth during the estimated time span from 2018 to 2030 (Ref). For instance, In November 2016, China’s State Council announced a national healthcare plan aimed at reducing population suffering from infectious diseases by 2020 (Ref). Such government initiatives will have a positive impact on overall market development within Asia Pacific region over next few years.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is one of the key growth drivers for the Interferon Alpha-2a biosimilar market. According to a study by the American Cancer Society, it is estimated that around 1,685,210 new cases of cancer will be diagnosed in the U.S. in 2017 and around 600,920 people will die from this disease. This growing prevalence of cancer is expected to drive demand for Interferon Alpha-2a biosimilars over the forecast period.
- Rising healthcare expenditure: The rising healthcare expenditure is another major factor fuelling growth of the Interferon Alpha-2a biosimilar market worldwide. According to a study by Deloitte Touche Tohmatsu Limited (Deloitte), global healthcare spending was estimated at USD 7 trillion in 2015 and it is projected to grow at a CAGR of 6% between 2016 and 2020, reaching USD 8 trillion by 2020. This increasing spending on healthcare is expected to boost demand for Interferon Alpha-2a biosimilars over the forecast period as they are more affordable than their branded counterparts..
Scope Of The Report
Report Attributes
Report Details
Report Title
Interferon Alpha-2a Biosimilar Market Research Report
By Type
Long-lasting Type, Ordinary Type
By Application
Hepatitis C, Hepatitis B, Other
By Companies
Roche, Biosidus, Zydus Cadila, Nanogen, Amega Biotech, Rhein Minapharm Biogenetics, PROBIOMED, 3sbio
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
245
Number of Tables & Figures
172
Customization Available
Yes, the report can be customized as per your need.
Global Interferon Alpha-2a Biosimilar Market Report Segments:
The global Interferon Alpha-2a Biosimilar market is segmented on the basis of:
Types
Long-lasting Type, Ordinary Type
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hepatitis C, Hepatitis B, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Roche
- Biosidus
- Zydus Cadila
- Nanogen
- Amega Biotech
- Rhein Minapharm Biogenetics
- PROBIOMED
- 3sbio
Highlights of The Interferon Alpha-2a Biosimilar Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Long-lasting Type
- Ordinary Type
- By Application:
- Hepatitis C
- Hepatitis B
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Interferon Alpha-2a Biosimilar Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Interferon alpha-2a biosimilar is a type of biologic therapy that is similar to the original interferon alpha-2a. It is used to treat various types of cancer.
Some of the major players in the interferon alpha-2a biosimilar market are Roche, Biosidus, Zydus Cadila, Nanogen, Amega Biotech, Rhein Minapharm Biogenetics, PROBIOMED, 3sbio.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Interferon Alpha-2a Biosimilar Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Interferon Alpha-2a Biosimilar Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Interferon Alpha-2a Biosimilar Market - Supply Chain
4.5. Global Interferon Alpha-2a Biosimilar Market Forecast
4.5.1. Interferon Alpha-2a Biosimilar Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Interferon Alpha-2a Biosimilar Market Size (000 Units) and Y-o-Y Growth
4.5.3. Interferon Alpha-2a Biosimilar Market Absolute $ Opportunity
5. Global Interferon Alpha-2a Biosimilar Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Type
5.3.1. Long-lasting Type
5.3.2. Ordinary Type
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Interferon Alpha-2a Biosimilar Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Application
6.3.1. Hepatitis C
6.3.2. Hepatitis B
6.3.3. Other
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Interferon Alpha-2a Biosimilar Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Interferon Alpha-2a Biosimilar Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Interferon Alpha-2a Biosimilar Demand Share Forecast, 2019-2026
9. North America Interferon Alpha-2a Biosimilar Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Application
9.4.1. Hepatitis C
9.4.2. Hepatitis B
9.4.3. Other
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Type
9.7.1. Long-lasting Type
9.7.2. Ordinary Type
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Interferon Alpha-2a Biosimilar Demand Share Forecast, 2019-2026
10. Latin America Interferon Alpha-2a Biosimilar Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Application
10.4.1. Hepatitis C
10.4.2. Hepatitis B
10.4.3. Other
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Type
10.7.1. Long-lasting Type
10.7.2. Ordinary Type
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Interferon Alpha-2a Biosimilar Demand Share Forecast, 2019-2026
11. Europe Interferon Alpha-2a Biosimilar Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Application
11.4.1. Hepatitis C
11.4.2. Hepatitis B
11.4.3. Other
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Type
11.7.1. Long-lasting Type
11.7.2. Ordinary Type
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Interferon Alpha-2a Biosimilar Demand Share, 2019-2026
12. Asia Pacific Interferon Alpha-2a Biosimilar Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Application
12.4.1. Hepatitis C
12.4.2. Hepatitis B
12.4.3. Other
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Type
12.7.1. Long-lasting Type
12.7.2. Ordinary Type
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Interferon Alpha-2a Biosimilar Demand Share, 2019-2026
13. Middle East & Africa Interferon Alpha-2a Biosimilar Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Application
13.4.1. Hepatitis C
13.4.2. Hepatitis B
13.4.3. Other
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Interferon Alpha-2a Biosimilar Market Size and Volume Forecast by Type
13.7.1. Long-lasting Type
13.7.2. Ordinary Type
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Interferon Alpha-2a Biosimilar Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Interferon Alpha-2a Biosimilar Market: Market Share Analysis
14.2. Interferon Alpha-2a Biosimilar Distributors and Customers
14.3. Interferon Alpha-2a Biosimilar Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Roche
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Biosidus
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Zydus Cadila
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Nanogen
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Amega Biotech
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Rhein Minapharm Biogenetics
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. PROBIOMED
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. 3sbio
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
